SSY Group (HKG:2005) obtained registration approval from China's National Medical Products Administration for Nicardipine Hydrochloride to become a bulk drug for the preparations on the market, a Monday filing with the Hong Kong bourse said.
Nicardipine Hydrochloride is used mainly to treat hypertension, according to the pharmaceutical company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.